Sponsor:	IO Biotech ApS
Protocol Number:	IO102-012
EudraCT Number:	2018-000139-28
Date of Clinical Study Report:	19 May 2023

The following table has been extracted from the final IO102-012 Clinical Study Report (dated 19 May 2023) and presents a summary of the results of the duration of response (DOR).

Secondary Endpoint: Duration of Response (including by PD-L1 score TPS <1% and TPS >1-49% for cohort B) – Both Phases

Number of Patients (ITT Population)	Cohort A		Cohort B	
	Exp A1[1] N=38	Control A2[2] N=16	Exp B1[3] N=39	Control B2[4] N=17
No. of patients with objective response	N=18	N=7	N=14	N=9
No. of DOR events	11 (61.1%)	2 (28.6%)	11 (78.6%)	8 (88.9%)
Median months to event	24.5	-	13	8.5
And 95% CI	[8.3 ; 33]	[9.0 ; -]	[6.7 ; 20]	[4.1 ; 21]
By PD-L1 expression:				
TPS <1% no. of pts with objective response	-	-	N=3	N=2
TPS <1% no. of DOR events	-	-	3 (100%)	2 (100%)
TPS <1% median months to event	-	-	15	13
And 95% CI	-	-	[6.9 ; -]	[4.1 ; -]
TPS 1-49% no. of pts with objective response	-	-	N=11	N=7
TPS 1-49% no. of DOR events	-	-	8 (72.7%)	6 (85.7%)
TPS 1-49% median months to event	-	-	10	8.5
And 95% CI	-	-	[5.8 ; -]	[4.6 ; 18]

For median months to event, missing numbers mean that these numbers could not be calculated.

[1] Exp A1 = Arm A (Phase I) + Arm A1 (Phase II)

[2] Control A2 = Arm A2 (Phase II)

[3] Exp B1 = Arm B (Phase I) + Arm B1 (Phase II)

[4] Control B2 = Arm B2 (Phase II)